MURA Mural Bio: Sof marja

Mural Oncology - MURA emitenti grafik logotipi

Mural Oncology plc (MURA) melanoma va buyrak saratoni davolash vositalarini ishlab chiqishga e'tibor qaratadi, biroq daromadli mahsulotlar va barqaror pul oqimining yetishmasligi bilan yuzlashmoqda. Umumiy sof marja ushbu muvozanatni aks ettiradi, bunda 0.00 ushbu ko'rsatkichning joriy qiymatidir. Ushbu tendentsiya kompaniyaning bozordagi mavqelarini himoya qilish uchun mustahkam patent to'sig'ini yaratuvchi shaxsiy protein platformalarining rivojlanishini ifodalaydi.

MURA: Mural Oncology Sof foyda normasi 21.02.2024 - 20.12.2025

muraloncology.com (MURA) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- aksiya kursi va ekspertlarning narx prognozi:
- kompaniya aksiyalari kapitallashuvi ma'lumotlari:
Kompaniyaning asosiy tahlili:Mural Oncology plc
Mural Oncology plc ishlab chiqargan mahsulot

Investorlar aktivning fundamental qiymatini aniqlash uchun ichki biznes samaradorligini baholashlari kerak. Sof rentabellik barcha operatsion va moliyaviy xarajatlar qoplanganidan keyin qolgan foyda qismini o'lchaydi. Joriy savdo marjalarini tahlil qilish pul oqimlarining barqarorligini aniqlashga yordam beradi. Mural Oncology (MURA) uchun ushbu ko'rsatkich nemvalekin platformasini kengaytirish xarajatlarini aks ettiradi. Kapitalni boshqarish samaradorligi aniqlikdagi saraton terapiyasi segmentiga kengayish davrida bu yerda juda muhimdir.

Raqobatdosh kompaniyalar tahlili

ONC: Sotuvning sof marjinal rentabelligi|Sof marja Halozyme Inc. (HALO)|Sof marja RevMed|Sotuvning sof rentabelligi AAPG (Ascentage Pharma Group)|Sotuvning sof marjinal rentabelligi CGON|UroGen Pharma - Sotuvning sof rentabelligi|Bicara Therapeutics - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof marjinal rentabelligi Personalis Inc PSNL|Erasca Oncology - Sotuvning sof marjinal rentabelligi|Sof foyda normasi DCTH (Delcath Corp)|YMAB: Sotuvning sof marjinal rentabelligi|AURA - Kompaniya sotuv marjasi|CADL (Candel Therapeutics Inc.) - Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi ARAY (Accuray)|Sof foyda bo'yicha sotuv rentabelligi SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Sof marja|Sof marja Citius Oncology, Inc. CTOR|HURA - Sof foyda bo'yicha sotuv rentabelligi|protaratx.com - Sotuvning sof marjinal rentabelligi|FATE - Sotuvning sof marjinal rentabelligi|WHWK: Sotuvning sof marjinal rentabelligi|TScan Therapeutics (TCRX) - Sotuvning sof marjinal rentabelligi|Sof marja Champions Oncology|Sof marja XBIT|Sotuvning sof marjinal rentabelligi CVM|Sof foyda bo'yicha sotuv rentabelligi OS Therapies Inc. OSTX|Sof marja Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Sof marja|ANL - Sof marja|Sof marja verupharma.com|TPST: Sotuvning sof marjinal rentabelligi|XLO - Kompaniya sotuv marjasi|Sof marja Renovaro|Kairos Pharma Ltd - Sof foyda marjasi|Sotuvning sof marjinal rentabelligi OKUR|CytoMed Therapeutics Limited (GDTC) - Sof foyda bo'yicha marjinallik|Sotuvning sof marjinal rentabelligi CRIS (Curis, Inc.)|APLM: Sotuvning sof rentabelligi|Tharimmune Corporation - Sotuvning sof marjinal rentabelligi|ADVB: Sof marja|GNPX: Sotuvning sof marjinal rentabelligi|CLDI (Calidi Biotherapeutics Inc.) - Sof marja|Sof marja Sunshine Biopharma, Inc.|Sotuvning sof marjinal rentabelligi xeneticbio.com|Sof marja Salarius (SLRX)|Sof foyda bo'yicha sotuv rentabelligi Purple Biotech PPBT|Sof marja American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Sof marja|Checkpoint Therapeutics Inc. - Sotuvning sof marjinal rentabelligi|Sof foyda normasi ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Sof foyda bo'yicha sotuv rentabelligi|Ikena Oncology, Inc. - Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi NTBL|VIRX: Sof foyda normasi|Sof marja MorphoSys Corporation (MOR)|NAYA - Sof marja|Sotuvning sof marjinal rentabelligi AAPGV (Ascentage)